Cambridge, UK; 8th January 2021

Atlantic Healthcare plc will be attending the prestigious 39th JP Morgan Healthcare Conference. This annual gathering is an invitation-only event, and this year is running online from January 11th to 14th.

If you are interested in exploring investment, during or around this conference, please email

If you are interested in exploring licensing opportunities, during or around this conference, please email

About Atlantic Healthcare

Atlantic Healthcare plc ( is a rare disease pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug, in development for ulcerative colitis and Crohn’s disease. It also owns renzapride, a novel therapy, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders associated with cystic fibrosis, systemic scleroderma and Parkinson’s disease.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.